Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Baxter
Dow
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Verapamil hydrochloride - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for verapamil hydrochloride and what is the scope of freedom to operate?

Verapamil hydrochloride is the generic ingredient in seven branded drugs marketed by Mylan, Recro Gainesville, Gd Searle Llc, Mt Adams, Abraxis Pharm, Bedford, Hospira, Intl Medication, Luitpold, Marsam Pharms Llc, Smith And Nephew, Solopak, Amneal Pharms Co, Anda Repository, Exela Pharma Scs Llc, Micro Labs, Somerset Theraps Llc, Pfizer, Apotex Corp, Cadila Pharms Ltd, Glenmark Generics, Ivax Sub Teva Pharms, Par Pharm, Pliva, Sun Pharm Inds Inc, Actavis Elizabeth, Heritage Pharms Inc, Mutual Pharm, Sun Pharm Industries, Warner Chilcott, Watson Labs, and Yaopharma Co Ltd, and is included in sixty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are seventeen drug master file entries for verapamil hydrochloride. Forty-one suppliers are listed for this compound.

Recent Clinical Trials for verapamil hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Leiden University Medical CenterPhase 4
HersenstichtingPhase 4
Innovatiefonds ZorgverzekeraarsPhase 4

See all verapamil hydrochloride clinical trials

Recent Litigation for verapamil hydrochloride

Identify potential future generic entrants

District Court Litigation
Case NameDate
Purdue Pharma L.P. v. PAR Pharmaceutical, Inc.2013-05-17
Endo Pharmaceuticals Inc., and Grunenthal GbmH v. Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc.2012-11-05
Purdue Pharma LP v. Sandoz Inc.2012-10-10

See all verapamil hydrochloride litigation

Medical Subject Heading (MeSH) Categories for verapamil hydrochloride
Synonyms for verapamil hydrochloride
( inverted question mark)-Verapamil hydrochloride
(??)-Verapamil hydrochloride
(?)-Verapamil hydrochloride
()-Verapamil hydrochlorid
(+-)-5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride
(+-)-Verapamil hydrochloride
(+/-)-VERAPAMIL HYDROCHLORIDE
(+/-)-Verapamil hydrochloride, >=99% (titration), powder
(+/-)-Verapamil hydrochloride, 99+%
(+/-)-Verapamil hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
(+/-)-Verapamil, Hydrochloride
(y)-Verapamil hydrochloride
152-11-4
152V114
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-isopropyl-pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]-2-propan-2-yl-pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-ylpentanenitrile;hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-isopropylpentanenitrile hydrochloride
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}-2-(methy lethyl)pentanenitrile, chloride
23313-68-0
36622-29-4
5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile hydrochloride
5-((3,4-Dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile monohydrochloride
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxy phenyl)-2-isopropylvaleronitrile hydrochloride
5-[(3,4-Dimethoxyphenethyl)methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile Hydrochloride
54236-EP2305219A1
54236-EP2308562A2
A816666
AB0018370
AC-16228
AC-8483
AC1L1Y4V
AC1Q3CE8
Akilen
AKOS005267117
AN-7969
Anpec
API0024301
Apo-Verap
ARONIS24174
Arpamyl LP
AS-16018
BBC/320
BC210130
BCP06465
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride
Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, monohydrochloride, (+-)-
Benzeneacetonitrile,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, monohydrochloride
Berkatens
BG0353
BIV1326
C27H38N2O4.HCl
C27H39ClN2O4
Calan (TN)
Calan SR
Calaptin
Calaptin 240 SR
Calcan hydrochloride
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
CAS-152-11-4
Caveril
CC-35585
CCG-39491
CHEMBL1280
Civicor
Civicor Retard
Coraver
Cordilox
Cordilox SR
Corpamil
Covera
Covera-HS
Covera-hs (TN)
CS-1685
D-365 hydrochloride
D00619
Dignover
Dilacoran HTA
DOQPXTMNIUCOSY-UHFFFAOYSA-N
DSSTox_CID_14095
DSSTox_GSID_34095
DSSTox_RID_79114
DTXSID2034095
Durasoptin
EINECS 205-800-5
Elthon
EN300-124002
EU-0101237
Flamon
FT-0603360
FT-0655647
Geangin
Harteze
Hexasoptin
Hexasoptin Retard
HMS1568M04
HMS1922J16
Hormitol
HSDB 3928
HY-A0064
I06-0615
Ikacor
Ikapress
IN1425
Inselon
Iproveratril hydrochloride
Isoptin Retard
Isoptin SR
Isoptino
Isotopin hydrochloride
Izoptin
Jenapamil
K-4825
Lekoptin
Lodixal
LP01237
LS-161199
LU 20175
Magotiron
Manidon
Manidon Retard
MFCD00055208
MLS000069485
MLS001055442
MLS002222213
MolPort-002-915-466
NCGC00024710-03
NCGC00094479-01
NCGC00094479-02
NCGC00094479-03
NCGC00094479-04
NCGC00094479-05
NCGC00258732-01
NCGC00261922-01
Novapamyl LP
Novo-Veramil
NSC 135784
NSC 272366
NSC-272366
NSC-657799
NSC-759589
NSC272366
NSC657799
NSC759589
Nu-Verap
Opera_ID_1210
Ormil
Pharmakon1600-02300307
Praecicor
Prestwick_440
Q-201923
Quasar
R853
Rapam
Robatelan
s4202
SC-18887
SCHEMBL33296
SMR000059109
SPECTRUM2300307
SR-01000000050
SR-01000000050-11
SR-01000000050-2
SR-01000000050-4
ST066908
ST24050346
SW196662-4
Tox21_201180
Tox21_501237
Univer
Univex
V 4629
Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-, monohydrochloride
Valeronitrile, 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropyl-,monohydrochloride
Vasolan (TN)
Vasomil
Vasopten
Vera-Sanorania
Verabeta
Veracaps SR
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil (hydrochloride)
Verapamil Acis
Verapamil AL
Verapamil Atid
Verapamil Basics
Verapamil chloridrate
Verapamil Ebewe
Verapamil HCl
Verapamil Henning
Verapamil Hydrochloride (Isoptin, Iproveratril, Calan)
Verapamil hydrochloride (JP17/USP)
Verapamil hydrochloride [USAN:JAN]
Verapamil hydrochloride [USAN:USP:JAN]
Verapamil Hydrochloride 1.0 mg/ml in Methanol (as free base)
Verapamil hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Verapamil hydrochloride, European Pharmacopoeia (EP) Reference Standard
Verapamil hydrochloride, United States Pharmacopeia (USP) Reference Standard
Verapamil Hydrochloride,(S)
Verapamil Injection
Verapamil MSD
Verapamil NM
Verapamil NM Pharma
Verapamil Nordic
Verapamil PB
Verapamil Riker
Verapamil SR
Verapamil Verla
Verapamil-AbZ
Verapamil, HCl
Verapamyl hydrochloride
Verapin
Verapress 240 SR
Verasal
Verasifar
Veratensin
Verdilac
Verelan (TN)
Verelan SR
Veroptinstada
Verpamil
Vetrimil
Vortac
Z2210978706
ZX-AFC000544
ZX-AS004533
Paragraph IV (Patent) Challenges for VERAPAMIL HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-07-20
VERELAN PM CAPSULE, EXTENDED RELEASE;ORAL verapamil hydrochloride 020943 2006-05-19
COVERA-HS TABLET, EXTENDED RELEASE;ORAL verapamil hydrochloride 020552

US Patents and Regulatory Information for verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 071367-001 Oct 1, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Hospira VERAPAMIL HYDROCHLORIDE verapamil hydrochloride INJECTABLE;INJECTION 070577-001 Feb 2, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Gd Searle Llc CALAN verapamil hydrochloride TABLET;ORAL 018817-004 Feb 23, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Luitpold VERAPAMIL HYDROCHLORIDE verapamil hydrochloride INJECTABLE;INJECTION 070225-001 Nov 12, 1985 DISCN No No   Start Trial   Start Trial   Start Trial
Mutual Pharm VERAPAMIL HYDROCHLORIDE verapamil hydrochloride TABLET;ORAL 070483-001 Sep 24, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Bedford VERAPAMIL HYDROCHLORIDE verapamil hydrochloride INJECTABLE;INJECTION 072888-001 Jul 28, 1995 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for verapamil hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996   Start Trial   Start Trial
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996   Start Trial   Start Trial
Recro Gainesville VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Medtronic
Colorcon
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.